KiranKTuragaMDMPH

General Surgery • New Haven, CT

Surgical Oncology (Other than Breast)

Chief of Surgical Oncology, Yale University School of Medicine

Join to view full profile

Dr. Turaga is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Turaga's full profile

Already have an account?

Office
310 Cedar Street
New Haven, CT 06520
Phone+1 203-785-3577

Education & Training

University of South Florida MorsaniFellowship, Complex General Surgical Oncology, 2008 - 2010
Creighton University School of Medicine (Omaha)Residency, Surgery, 2003 - 2008
All India Institute of Medical SciencesClass of 2002

Certifications & Licensure

CT State Medical License 2022 - 2024
IL State Medical License 2016 - 2023
OR State Medical License 2021 - 2022
WI State Medical License 2010 - 2017
FL State Medical License 2009 - 2011
PA State Medical License 2009 - 2009

Awards, Honors, & Recognition

Fellow American College of Surgeons

Clinical Trials

Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma Start of enrollment: 2018 Oct 10
Active, not recruiting
Not Applicable
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Start of enrollment: 2025 Sep 30
Not yet recruiting
Phase 2
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma Start of enrollment: 2021 Dec 01
Completed
Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer Start of enrollment: 2024 Mar 14
Recruiting
Phase 2
Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System Start of enrollment: 2015 Apr 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

168 citations
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis
Joseph H. Helm, John T. Miura, Jason A. Glenn, Rebecca K. Marcus, Gregory Larrieux
Annals of Surgical Oncology. 2015-05-01
33 citations
A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Soc...
A. Arjona-Sanchez, Jesus Esquivel, Olivier Glehen, Guillaume Passot, Kiran K. Turaga
Surgical Endoscopy. 2019-03-01
25 citations
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Álvaro Arjona-Sánchez, O. Aziz, Guillaume Passot, George I. Salti, Jesus Esquivel
European Journal of Surgical Oncology. 2021-06-01

Journal Articles

Estimating Surgical Risk for Patients with Severe Comorbidities
Muneera R Kapadia, Elizabeth C Poli, Kiran K Turaga, JAMA

Lectures

Esophageal/Gastric Malignancy
Milwaukee, WI - 10/27/2014

Press Mentions

6 Recent Moves from the Nation's Leading Cancer CentersJuly 25th, 2022
New Opdivo/Yervoy Mesothelioma Clinical Trial Begins SoonOctober 7th, 2021
Upfront HIPEC May up Survival in Ovarian CancerAugust 25th, 2020
Join now to see all